FindTrial
Sign In

OLANZAPINE VS LAMOTRIGINE ADD-ON TO LITHIUM:EFFICACY ON ANXIETY SYMPTOMS IN REMITTING BIPOLAR PATIENTS

OLANZAPINE VS LAMOTRIGINE ADD-ON TO LITHIUM:EFFICACY ON ANXIETY SYMPTOMS IN REMITTING BIPOLAR PATIENTS

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-001606-66-IT
Enrollment
Unknown
Registered
2005-07-12
Start date
2005-06-16
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EFFICACY ON ANXIETY SYMPTOMS IN REMITTING BIPOLAR PATIENTS MedDRA version: 6.1 Level: PT Classification code 10057667

Interventions

Trade Name: ZYPREXA VELOTAB*28 CPR 5 MG Pharmaceutical Form: Tablet INN or Proposed INN: Olanzapine CAS Number: 132539-06-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration

Sponsors

AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026